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InﬂammationPathogens and sterile insults both result in an inﬂammatory response. A signiﬁcant part of this response is
mediated by cytosolic machinery termed as the inﬂammasome which results in the activation and secretion
of the cytokines interleukin-1β (IL-1β) and IL-18. Both of these are known to result in the activation of an
acute inﬂammatory response, resulting in the production of downstream inﬂammatory cytokines such as
tumor necrosis factor (TNF-α), interferon-gamma (IFN-γ), chemotaxis of immune cells, and induction of tis-
sue injury. Surprisingly this very acute inﬂammatory pathway is also vital for the development of a full
ﬁbrogenic response in a number of organs including the lung, liver, and skin. There is evidence for the
inﬂammasome having a direct role on tissue speciﬁc matrix producing cells such as the liver stellate cell,
and also indirectly through the activation of resident tissue macrophage populations. The inﬂammasome re-
quires stimulation of two pathways for full activation, and initiating stimuli include Toll-like receptor (TLR)
agonists, adenosine triphosphate (ATP), particulates, and oxidative stress. Such a role for an acute inﬂamma-
tory pathway in ﬁbrosis runs counter to the prevailing association of TGF-β driven anti-inﬂammatory and
pro-ﬁbrotic pathways. This identiﬁes new therapeutic targets which have the potential to simultaneously
decrease inﬂammation, tissue injury and ﬁbrosis. This article is part of a Special Issue entitled: Fibrosis:
Translation of basic research to human disease.
Published by Elsevier B.V.1. Introduction
Fibrogenesis is a common widespread pathophysiological response
in many tissues after chronic or repetitive injury including infections,
autoimmune reactions, and mechanical injury [1–4]. The initial insults
can be ampliﬁed by an inﬂammatory response leading to ﬁbrosis, depo-
sition of extracellular matrix, scar formation, and organ failure [3,5–7].
Innate immune cells residing in tissues recognize pathogen invasion
with intracellular or surface-expressed pattern recognition receptors
(PRRs) by detecting pathogen-associated molecular patterns (PAMPs)
[8]. PPRs can also be activated bydamage-associatedmolecular patterns
(DAMPs) from injured cells leading to sterile inﬂammation to distin-
guish from that induced by pathogens [9]. Inﬂammasomes are a group
of protein complexes that recognize a diverse set of inﬂammation-
inducing stimuli that include PAMPs and DAMPs and that control acti-
vation of the proteolytic enzyme caspase-1, which in turn regulates
maturation of the pro-inﬂammatory cytokines interleukin-1β (IL-1β)
and IL-18 [10,11]. Inﬂammasomes have been found to regulate impor-
tant aspects of inﬂammation and tissue repair such as ﬁbrogenesis, a
consequence of inﬂammatory response [12]. Recent studies haves: Translation of basic research
es, Yale University, TAC S223A,
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al).
.V.characterized distinctmolecular activationmechanisms for several sen-
sor proteins and have described the important implication of those
components in immune-mediated pathogenesis in humans. We review
recent research progress, discuss the different aspects that have been
proposed for inﬂammasome involvement in ﬁbrogenesis during disease
development, and highlight the challenges and future directions for this
ﬁeld.
2. Sterile inﬂammation
Inﬂammation derived by the innate immune response has evolved to
efﬁciently combat infectionwith pathogenicmicroorganisms and is crit-
ical to host defense. However, such innate mechanisms can also be acti-
vated as result of a sterile cell death or injury in the absence of any
microorganism, and has been termed ‘sterile inﬂammation’ [13]. Similar
to microbial-induced inﬂammation, sterile inﬂammation is character-
ized by the accumulation of neutrophils andmacrophages, and the pro-
duction of pro-inﬂammatory cytokines and chemokines, especially
tumor necrosis factor (TNF) and interleukin 1-β (IL-1β), as well as reac-
tive oxygen species [13,14]. Sterile inﬂammation can be induced by
many DAMPs including adenosine triphosphate (ATP) and uric acid,
which have the ability to activate inﬂammation in the non-infectious
immune response. A large and varied number of DAMPs applied to self
molecules have been identiﬁed as endogenous factors that can be re-
leased or generated into the extracellular environment by dying cells
or secondarily abnormal metabolism, and trigger sterile inﬂammation
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DAMPs in damaged tissues can vary greatly depending on the type of
cell and injured tissue, as illustrated by DAMPs released from parenchy-
mal cells after drug-induced hepatocyte cell death [16]. Prototypical
DAMPs derived from necrotic cells include intracellular proteins, such
as the chromatin associated protein high-mobility group box 1
(HMGB1) [17], heat shock proteins (HSPs) [18,19], and proteins derived
from the extracellular matrix that are generated following tissue injury,
such as hyaluronan, heparin sulfate and biglycan. These are generated as
a result of proteolysis by enzymes released from dying cells or by prote-
ases activated to promote tissue repair and remodeling [20,21].
Non-protein DAMPs are released or generated during cell death or pu-
rinemetabolites, such as ATP [22] and uric acid [23]. Recently,mitochon-
dria have emerged as organelles that provide a rich source of DAMPs
including mitochondrial DNA, formyl peptides, cytochrome C and ATP.
Such a concentration of DAMPsmakes mitochondria very potent stimu-
lators of inﬂammation [24,25]. The variety of DAMP components
derived from mitochondria further increases their ability to induce in-
ﬂammation as they can provide the full range of signals required to ini-
tiate sterile inﬂammation. In addition to those typical DAMP molecules,
some biologically active pro-inﬂammatory cytokines and chemokines,
such as IL-1α [26] and IL-33 [27] can be released by necrotic cells,
serve a similar function as conventional DAMPs. The importance of cell
death in relation to the production of DAMPs and sterile inﬂammation
is that it provides a pathway of regulated pro-inﬂammatory type of
cell death. However, HMGB1 can be secreted by activated macrophages
in response to LPS, TNF and TGF-β [28]. This conﬁrms the functional
pro-inﬂammatory actions of HMGB1 independent of cell death.
A wide range of in vivo and external particulates have been found
to trigger sterile inﬂammation, in some cases those particulates elicit-
ed response associates with prominent ﬁbrogenesis. These particles
include inorganic (silica dioxide) [29], organic (cholesterol), crystal-
line (uric acid crystals), or amorphous such as alum [30,31]. Initially
it seems unlikely that signiﬁcant amounts of organic particulates are
present in vivo, however recent examination of liver tissues from
humans and mice have shown that with fat-induced inﬂammation,
but not simple steatosis, cholesterol crystals are present inside hepa-
tocytes and come into contact with Kupffer cells [32]. When other
non-organic particulates such as talc in intravenous drug users
enter organs such as the liver there is also a strong ﬁbrotic response
[33]. The further results from our research group have shown that im-
plantation of biomaterials and devices into soft tissues leads to the
development of a sterile foreign body response (FBR), which can in-
terfere with implant function and eventually lead to failure [34].
Most of these parts for a number of these particles the inﬂammatory
response results in tissue damage and its attendant ﬁbrogenesis can
lead to loss of function. Approximately 20 DAMPs have been identi-
ﬁed and it is likely that many others are present in vivo.
3. Components of inﬂammasomes
Until recently, much more was known about how innate immunity
is activated by pathogens than by sterile particles and dead cells. The in-
nate immune system possesses multiple families of germ-line encoded
PRRs. These PRRs include the Toll-like receptors (TLRs), NOD-like recep-
tors (NLRs), C-type lectin receptors (CLRs), and several other receptors
[35–37], all of which contribute to immune activation in response to di-
verse stimuli. These include infectious and noninfectious materials that
can cause tissue damage, and endogenous molecules that are released
during cellular injury. Activation of these receptors ultimately leads to
the production of cytokines that drive the inﬂammatory response.
DAMPs are the best characterized candidates that know to activate
PRRs and trigger sterile inﬂammation. Like all the other innate immune
receptor molecules, the NLR proteins are involved in sensing the pres-
ence of pathogens via PAMPs; however, they also can detect endoge-
nous danger or stress signals via DAMPs. A subset of NLRs forms acomplex with ASC (apoptosis-associated speck-like protein containing
a CARD) to activate caspase-1 and induce maturation and secretion of
important pro-inﬂammatory cytokines such as interleukin-1β (IL-1β)
and IL-18, whose potent pro-inﬂammatory activities direct host re-
sponses to infection and injury. Those complexes ﬁrstly were termed
as inﬂammasome by the Tschopp research group [38]. The diverse func-
tions of inﬂammasomes in antimicrobial responses, as well as in multi-
faceted diseases such as acute liver injury and metabolic syndrome,
have become evident. Importantly, mutations in components of
inﬂammasome complexes have been associated with a propensity for
the development of several immune-mediated diseases in humans.
The inﬂammasome is composed of a sensory molecule that is a
member of the family of nucleotide-binding oligomerization domain
(NOD)-like receptors (NLRs), which can be divided into three
subfamilies: NLRP, NOD and ICE-protease-activating factor (IPAF)/neu-
ronal apoptosis inhibitory protein (NAIP) based on their molecular
structure and function [10]. These sensory molecules interact with the
intermediary adaptor molecule ASC, which in turn can activate cellular
proteases. The sensory molecules are cytoplasmic pattern-recognition
receptors that recognize a range of molecules ranging from PAMPs to
danger signals, such as uric acid and a variety of others. The human
NLR family consists of 22 members that can be sub-grouped based on
their N-terminal domain which include caspase-recruitment domain
(CARD), pyrin domain (PYD), and baculovirus IAP repeat domain (BIR).
Upon activation, NLR family members form the multiprotein com-
plexes called the inﬂammasome. In addition, the cytosolic AIM2 (absent
in melanoma 2) molecule is also capable of forming an inﬂammasome
complex. The inﬂammasome serves as a platform for activation of the
cysteine protease caspase-1 which cleaves the pro-forms of the cyto-
kines IL-1β and IL-18 to their active and secreted forms. Caspase-1
may also possess additional functions including regulation of metabo-
lism [39] and unconventional protein secretion [40]. The NLRP3
inﬂammasome has been associated with a wide range of diseases in-
cluding infectious, auto-inﬂammatory, and autoimmune disorders. Bac-
terial, fungal, viral, and protozoan parasitic pathogens have all been
demonstrated to activate the NLRP3 inﬂammasome [41,42]. NLRP3 is
likely responding to the cellular stress induced by the infectious agents
and DAMPs and mitochondria are likely central to co-ordinating this
process.
IL-1β is activated by caspase-1 and is a proximal pro-inﬂammatory
cytokine that broadly affects inﬂammatory processes. IL-1β is synthe-
sized as a pro-protein without a typical signal sequence that would
allow its secretion, and instead its activation and cellular release are
controlled by caspase-1 [43]. Caspase-1 is also responsible for the secre-
tion of IL-1α and ﬁbroblast growth factor-2 through an unconventional
protein secretion pathway [40]. Caspase-1 is constitutively expressed as
pro-caspase-1, but it remains inactive in the cytoplasm until inﬂamma-
tory effector cells such as monocytes and macrophages receive appro-
priate stimuli. Known activators are changes in the intracellular ionic
environment and bacterial products such as lipopolysaccharide (LPS)
and peptidoglycan [44,45]. Inﬂammasome machinery recruits pro-
caspase-1 either directly through homotypic binding of CARD or indi-
rectly through PYD of ASC protein.
4. Regulation of inﬂammasome activity
In the current model of inﬂammasome activation there are two dis-
tinct signals. The ﬁrst signal can be triggered by various PAMPs follow-
ing TLR activation signal as well as IL-1R signaling, and the activation of
tumor necrosis factor receptor (TNF-R) (Fig. 1). This priming signal
leads to transcription activation of the genes encoding pro-IL-1β, pro-
IL-18 and NLRP3 [46,47]. The second signal is provided by various
inﬂammasome ligands through cytosolic NLR inﬂammasome activation
leading the cleavage of pro-IL-1β and pro-IL-18 into the active forms
[48,49]. In the second signal model, after phagocytosis of large crystals
such as monosodium urate (MSU), silica, asbestos and aluminum salts,
Fig. 1. Inﬂammasome signaling pathways leading to mature IL-1β and IL-18 production: Two major signaling pathways are known to be required in the production of mature IL-1β
and IL-18. Signal-1: activation of this pathway results in the production of pro-IL-1β and pro-IL-18 through interaction of various DAMPs/PAMPs and cytokines like TNF-αwith TLRs
and TNFR. Signal-2: this leads to inﬂammasome activation through multiple signaling pathways. MSU and other crystals are internalized through phagocytosis that results in the
formation of phagolysosome. The phagocytosed crystals cause phagolysosomal membrane damage and release of cathepsin B that triggers inﬂammasome activation. The other
pathway of inﬂammasome activation is through potassium efﬂux that takes place when ATP which was released from dying cells binds with the P2X7 receptor. During bacterial
infection certain toxins that enter the cells through pore formations are released and may lead to inﬂammasome activation. The activation of inﬂammasome results in the gener-
ation of serine proteases like caspase-1 from pro-caspase-1. This caspase-1 then cleaves pro-IL-1β and pro-IL-18 to mature IL-1β and IL-18 that are secreted out of the cell through
secretory vesicles to serve as key mediators for systemic inﬂammation. Abbreviations: DAMPs, disease associated molecular patterns; PAMPs, pathogen associated molecular
patterns; MSU, monosodium urate; ATP, adenosine triphosphate; ROS, reactive oxygen species; TLRs, Toll-like receptors; IL-1β, interleukin-1 beta; IL-18, interleukin-18; TNF-α,
tumor necrosis factor-alpha; TNFR, tumor necrosis factor receptor.
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NLRP3 (Fig. 2). Notably, one model is the binding of extracellular ATP
to P2X7 leading to a potassium efﬂux from the cell. This efﬂux leads to
the opening of large-pored pannexin-1 channels into the membrane,
through which PAMPs and DAMPs can access the cell and directly
activate NLRP3 [50]. In addition, the reactive oxygen species (ROS) gen-
erated after exposure to PAMPs and DAMPs is proposed to lead to the
formation of the NLRP3 inﬂammasome. It remains unclear, however,
how these diverse signals might converge to activate the NLRP3
inﬂammasome, although a recent publication suggests that ROS is
through the ATP dependent potassium efﬂux and lysosomal rupture,
and can activate the inﬂammasome via the ROS-sensitive ligand,
thioredoxin-interacting protein [51]. However signal 1 might be re-
quired only for Nlrp3 activation, not other inﬂammasomes such as
NLRC4 and AIM2 [52], since the expression of inﬂammasome sensors,
in particular NLRP3, is relatively low in many cell types and requires a
priming signal to be induced [53]. Our unpublished results havedemonstrated that either the ﬁrst and second signal of inﬂammasome
can be modiﬁed by endogenous danger molecule called adenosine,
which is usually released from injured cells or generated during ATP
metabolism, in which adenosine sustained the amplitude and duration
of inﬂammasome activity through a distinct intracellular signaling
pathway.
In addition to ATP, cells release other danger signals to activate the
inﬂammasome. For example uric acid crystal particles activates Nlrp3
inﬂammasome to produce active IL-1β, and macrophages from mice
deﬁcient in the inﬂammasome components of caspase-1, Nlrp3, and
ASC, have a highly reduced crystal-induced IL-1β activation capacity
[54]. These observations suggest a mechanism whereby immune
cell activation can be triggered by solid structures via membrane
lipid alteration without the requirement for speciﬁc cell-surface re-
ceptors [55]. Similarly, our group has reported that acute inﬂammato-
ry response to biomaterial particulates requires the inﬂammasome
components of Nlrp3, ASC, caspase-1, as well as plasma membrane
Fig. 2. Inﬂammasome activation and IL-1β production through Syk pathway: uric acid is released from dying cells during infection and inﬂammation that crystalizes into MSU crys-
tals. MSU crystals when in access bind to TLR 2/4 receptor and lead to NFκB-mediated pro-IL-1β production. MSU crystals may also bind to cell membrane cholesterol and trigger
lipid sorting, which leads to Syk recruitment by ITAM containing receptors enriched in the lipid rafts. At this point two pathways may evolve that lead to mature IL-1β production.
i) Syk activation may lead to pro-IL-1β production through CARD9 and NFκB signaling pathway. ii) Syk recruitment turns on PI3K-mediated phagocytosis of MSU crystals. The
phagocytosed MSU crystals cause phagolysosomal membrane damage and release of cathepsin B that triggers NLRP3 inﬂammasome activation. Also phagolysosomal destabilization
may result in potassium efﬂux and generation of ROS to induce inﬂammasome activation. Activation of inﬂammasome results in the production of mature IL-1β from pro-IL-1β
through caspase-1 that is secreted out of the cell through secretory vesicles to serve as a key mediator for systemic inﬂammation. Question marks indicate suspected links.
Abbreviations: Syk, spleen tyrosine kinase; ITAM, immunoreceptor tyrosine-based activation motif; PI3K, phosphatidylinositol 3-kinase; MSU, monosodium urate; ROS, reactive
oxygen species; TLR, Toll-like receptor; IL-1β, interleukin-1β; CARD9, caspase recruitment domain-containing protein 9.
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inﬂammasome in cell–biomaterial interactions and in the develop-
ment of particulate elucidated inﬂammatory response [34].
Recent reports reveal a crosstalk between cellular stress-
associated processes such as autophagy and inﬂammasome activity.
Autophagy is a cytoprotective process involving the degradation of
cellular components through the lysosomal machinery, in which the
autophagosome targets those cellular components for degradation in
the lysosome, and recycles the constitute molecules [56]. Strikingly,
mice lacking Atg16L1, an autophagy component limits production of
the inﬂammatory cytokines IL-1β and IL-18 [57]. This has been sug-
gested to be a result of the impaired clearance of defective mitochon-
dria resulting in elevated levels of ROS, hinting at an involvement of
NLRP3 as sensor [58,59]. Given that NLRP3 activation is suppressed
by ROS blockade and autophagy negatively regulates ROS generation
[59,60], it seems like that autophagic suppression of ROS indirectly in-
hibits inﬂammasome activity.
Inﬂammasome activity can also be regulated either through secreted
factors or cell–cell interactions, CD4+effector andmemory T cells were
demonstrated to suppress NLRP1 and NLRp3 inﬂammasome-mediated
caspase-1 activity and IL-1β secretion [61]. Examples of cytokines thatmediated negative regulation of inﬂammasome activity is provided;
type I interferon (IFN-I) was also found to inhibit IL-1β secretion as
well as inﬂammasome activation [62]. The inhibition is dependent on
the interactions between T cells and macrophages or dendritic cells
respectively, leading transcriptional and post-transcriptional down
regulation of inﬂammasome activity [61,62].
5. Activation of the inﬂammasome in different cell populations
It has been long assumed that immune cells of myeloid origin, in-
cluding monocytes, macrophages, neutrophils, and dendritic cells are
the only sources of IL-1β as well as the localization of inﬂammasome
components [63]. However, there is an increasing evidence that
inﬂammasomes exist and are functionally active in several tissues, in-
cluding lung, liver, kidney and skin, and a variety cell types express
inﬂammasome components including T cells, myoﬁbroblasts/ﬁbroblasts
[64], keratinocytes, epithelial cells, hepatocytes, and hepatic stellate cells
[65–70,70–73,66]. The recent evidence has shown that both Nlrp1 and
Nlrp3 expression is present in myeloid and non-myeloid cells, highest
levels of Nlrp1 and Nlrp3 exist in peripheral blood leukocytes, T cells,
and Langerhans cells. Nlrp1 is present in glandular epithelial structures
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tissue distribution with expression mainly in non-keratinizing epithelia
in the oropharynx, esophagus, and ectocervix [67]. In the liver NLRP1, 2,
3, 6, 10, 12, and NLRC4 are expressed at the mRNA level [67]. Kupffer
cells, the liver resident macrophages, can produce signiﬁcant amounts
of IL-1β [74] and express most of the NLRs [75].
5.1. Acute activation verses chronic activation
The role of inﬂammasome components was identiﬁed in the acute
inﬂammatory response of macrophages to uric acid crystals [12]. This
has been followed by a demonstration of a role for inﬂammasome
components in a surprisingly wide range of biological processes
some of which like gout are acute, but others such as ﬁbrosis occur
over months and years [76]. The proposed activation paradigm of sig-
nal 1 (TLR-mediated transcriptional up-regulation) and signal 2 (as-
sembly of inﬂammasome components and cleavage of caspase-1)
works well for acute inﬂammatory responses. However for chronic
inﬂammation there is a defect in the proposed scheme. The defect is
that signal 1 has an acute time course. At the mRNA level there is a
peak in pro-IL-1β at 3–5 h, and at the protein level at 16–18 h. This
is followed by a rapid decline by 24 h. This acute response cannot
be converted into a sustained response by simply providing a
sustained signal with a TLR agonist. This has been recognized in
many forms and is best characterized for the TLR4 ligand LPS, and la-
beled LPS tolerance [77]. This is a complex and broad phenomenon
with alterations in the TLR signaling pathway in multiple places
[77]. The breadth of LPS tolerance is demonstrated by the fact that
there is a loss of response to other TLR ligands as well, described as
heterotolerance. Sustained exposure to stimuli providing signal 2
also does not result in sustained activation, but rather cell death.
This occurs with signals such as ATP and also particulates such as
uric acid crystals. This highlights that we do not yet understand
which stimuli result in sustained inﬂammasome activity. The identity
of these signals is speculative but they would have to be maintained
for extended periods and be pro-ﬁbrogenic. There are likely many
other inputs into each type of cell which can inﬂuence inﬂammasome
activity and a prime candidate for sustained activation of the
inﬂammasome is adenosine which is elevated in tissues during injury
and inﬂammation and has a well documented pro-ﬁbrotic role.
The kinetics of macrophage activation in liver ﬁbrosis has at least
two phases. During the development of ﬁbrosis liver macrophages con-
tribute to the deposition of amatrix, and during the recovery phase they
contribute tomatrix degradation [78]. The reducedﬁbrosis inmice lack-
ing inﬂammasome components suggests that the inﬂammasome is im-
portant in at least the initial phase ofmacrophage dependent deposition
of ﬁbrosis. It will require a generation of timed and inﬂammasome se-
lective depletion of inﬂammasome components to address the role of
inﬂammasome components during the resolution of ﬁbrosis.
Immune cells other than tissue macrophages are known to have an
important role in liver ﬁbrosis. These include natural killer (NK) and
NK-T cells, T cells with Th1, Th2, Th17 and Th22 skewing aswell as den-
dritic cells [79]. The role of inﬂammasome components inmany of these
cell populations is just beginning to be identiﬁed. The best characterized
is inﬂammasome-mediated dendritic cell activation particularly in re-
sponse to particulate adjuvants such as alum. The role of dendritic
cells in different stages of NASH-induced inﬂammation and ﬁbrosis
was recently clariﬁed when it was shown that ablation of DC resulted
in greater ﬁbro-inﬂammation [79]. Dendritic cells are known to develop
an activated phenotype in ﬁbrotic liver diseases, but it remains to be
tested if this is dependent on inﬂammasome components [80].
6. Inﬂammasome components in organ models of ﬁbrosis
The common experimental tools available to investigate the role
of inﬂammasome components in organ speciﬁc ﬁbrosis are micewith deﬁciencies in various inﬂammasome molecules, use of receptor
agonists and antagonists, and detection of release of DAMPs. The ﬁrst
two of these approaches do not distinguish between the contribution
of PAMPs and DAMPs to liver injury, and the third provides indirect
evidence that a DAMP may be responsible. More convincing evidence
comes from the demonstration that removal of a particular DAMP re-
sults in less liver pathology, and this has been done for HMGB1 in IR
and APAP toxicities [17,81]. A number of these approaches have
been tried in lung, liver, skin and kidney ﬁbrosis but they have not
all been applied in all of these.
7. Lung ﬁbrosis
Pulmonary ﬁbrosis occurs in response to a number of insults includ-
ing exposure to toxins in cigarette smoke, and hypersensitivity to aller-
gens in bacterial, fungal and animal products. In addition particulates
such as silica and asbestos induce inﬂammation and ﬁbrosis and it
also occurs secondary to connective tissue diseases such as scleroderma
and certain drugs such as bleomycin. The lungs were one of the ﬁrst or-
gans in which a role for inﬂammasome components was demonstrated
using a bleomycin injury model [82]. Mice lacking the IL-1R and the
adaptor ASC had signiﬁcantly less neutrophilic and lymphocytic inﬁl-
trates. Bone marrow chimeras constructed using MyD88 deﬁcient
cells and mice gave a very clear result, with the development of inﬂam-
mation when KO bone marrow was injected into WT mice, but not
when wild-type bone marrow was injected into KO mice. Critically
there was also reduced matrix remodeling and ultimately less ﬁbrosis
at day 11 after bleomycin nasal installation. Very direct evidence for a
role of IL-1R in lung inﬂammation and ﬁbrosis was provided by direct
installation of IL-1β into the lungs. After 7 days there was inﬂammation
and matrix deposition. The in vivo role of IL-1β was demonstrated by
using the IL-1R antagonist given at the same time as bleomycin. This
work has been extended to identify uric acid as one of the proximal sig-
nals for inﬂammasome activation in bleomycin lung injury [12]. The re-
duction of uric acid synthesis by using an inhibitor of uric acid synthesis
or uricase to increase uric acid breakdown resulted in reduced lung in-
ﬂammation, repair and ﬁbrosis. The addition of uric acid recapitulated
in lung inﬂammation in an NLRP3 and IL1-R dependent manner. This
seems very surprising because there is a requirement for uric acid
crystals in the lung, not just soluble uric acid for activation of the
inﬂammasome.
The induction of lung injury by a single intra-nasal dose of pancre-
atic elastase results in the destruction of the matrix and an acute in-
ﬂammatory response, presumably by the release of DAMPs. In this
model, which has features of chronic obstructive pulmonary disease,
the development of emphysema was dependent on NLRP3 and
IL-1R1, and importantly could be inhibited by a clinically available
IL-1R antagonist [83]. Exogenous particulates are also known to in-
duce inﬂammasome activation. In some professions such as mining,
workers repeatedly inhale particles of silica which can result in a
chronic interstitial pulmonary disease with progressive ﬁbrosis [84].
Inhalation of asbestos results in similar chronic lung ﬁbrosis [84]. A
role for pulmonary macrophages was suspected to have a major role
in the lung ﬁbrosis because macrophages from patients were shown
to produce high levels of IL-1β and in vitro exposure of macrophages
to silica crystals results in the production of IL-1β [85]. It has been
shown that the in vitro production of IL-1β by macrophages and
the in vivo production of ﬁbrosis were dependent on NLRP3 and
caspase-1 [86].
8. Liver ﬁbrosis
In commonwith other organs repeated and chronic injury results in
a severe ﬁbrotic response in a signiﬁcant proportion of people. This is
seen with chronic viral infections, and non-infectious etiologies. The
non-infectious etiologies are of particular interest as in the developed
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coholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), is-
chemia–reperfusion (IR) and drug-induced liver injury are the major
non-infectious liver diseases.
Alcoholic liver disease encompasses a spectrum of pathologies
which range from mild steatosis to a fulminant hepatitis, to the silent
development of ﬁbrosis. The factors which result in certain people to
develop these pathologies is not well understood, but it is clear that
there is a role for inﬂammation and ﬁbrosis in the ultimate organ dys-
function. A role for TLRs speciﬁcally TLR4 was demonstrated by using
receptor deﬁcient mice [87]. With respect to the ability of PAMPs and
DAMPs to activate TLRs, the ability of reduction in the bacterial load of
the intestine to improve liver damage pointed to a major role for
PAMPs [88]. A single study has extensively examined the role of
many inﬂammasome components in a mouse model of alcoholic
liver disease [89]. In mice lacking ASC, caspase-1 or IL-1R there is sig-
niﬁcantly less steatosis, inﬂammation and liver injury. This was asso-
ciated with a reduction in a number of inﬂammatory cytokines.
Alcohol-induced liver injury results in a relatively mild ﬁbrosis, but
this was signiﬁcantly reduced in caspase-1 deﬁcient mice. The use
of bone marrow chimeras revealed that the requirement of
inﬂammasome components was on bone marrow derived, rather
than parenchymal cells. This is consistent with studies in obesity-
induced insulin resistance and NASH where the requirement for
TLR2, TL4 and JNK1 in the development of inﬂammation and insulin
resistance is on bone marrow-derived cells [90–92]. There was a re-
duction in the ﬁbrotic area in liver histology, a reduction in gene ex-
pression for TGF-β1 and pro-Col1α1, and serum levels of PIIINP,
TIMP-1 and hyaluronic acid. Also daily administration of IL-1R antag-
onist was able to reduce the development of alcohol-induced hepati-
tis, to reduce the progression of injury, and to accelerate the rate of
improvement after stopping alcohol. The effect of IL-1R antagonist
on ﬁbrosis was not assessed, but it is likely that if given before initia-
tion of injury it would minimize the development of ﬁbrosis. Its ef-
fects on established ﬁbrosis are less predictable.
Non-alcoholic steatohepatitis (NASH) has many of the histological
and biochemical features of ASH, but does not have the ﬂares of acute
life-threatening hepatitis and liver failure [93]. With the obesity epi-
demic in developing countries the prevalence of NASH and its precur-
sor non-alcoholic fatty liver disease (NAFLD) is increasing. Although
the clinical course is usually asymptomatic, similar to ASH there is a
clear progression to ﬁbrosis and cirrhosis in a signiﬁcant minority of
patients. Some of the difﬁculties with NASH have been the low level
of liver injury in animal models, and the subsequent difﬁculty in dem-
onstrating elevations in DAMPs. Analogous to ASH elevations in the
TLR4 ligands LPS have been demonstrated in rodent models, and in
human NASH due to intestinal bypass [94]. There is a controversy as
to the role of free fatty acids in activating Toll receptors, but there
are some reports of FFA activating TLR4 [95]. In the absence of TLR4
and TLR9 many aspects of NASH including histological score, hepato-
cyte apoptosis, ALT and ﬁbrogenic markers are reduced [74,96,97].
TLR9 is required for normal amounts of IL-1β production from
Kupffer cells in NASH, which induces hepatocyte death and HSC acti-
vation. IL-1β also induces lipid metabolism and hepatocyte steatosis.
These studies also provided insight into an open question regarding
IL-1β in inducing tissue injury. It relates to the fact that the IL-1 re-
ceptor does not have a death domain, and it was unclear how it can
induce hepatocyte death. It was recently demonstrated that although
IL-1β cannot induce cell death by itself, it sensitizes hepatocytes to
signal from conventional cell death signals such as TNF-α. [74,98].
Ischemia–perfusion (IR) injury is not associated with ﬁbrosis but
is an important clinical condition, and also an experimental model
to understand how the liver responds to injury [99]. IR injury encom-
passes at least two different stages of insults, with an initial injury
during cold preservation during which sinusoidal cells are predomi-
nantly damaged [100]. This is followed by a period of warm IRwhich is associated with ischemic damage, and upon reperfusion an
inﬂammatory response which is driven mostly by the innate immune
system [101]. As for most models the role of TLR4 was initially tested
on IR injury and analogous to the data of inﬂammasomes in alcoholic
liver injury there was a requirement for TLR4 on non-parenchymal
cells [102]. In contrast to alcohol-induced liver injury there is a direct
evidence for DAMPs driving IR injury because there is an elevation in
the DAMP HMGB1, and its inhibition results in a reduction in IR in-
jury. In vivo evidence for a requirement of the NLRP3 inﬂammasome
comes from experiments in which there was silencing of the NLRP3
gene. NLRP3 speciﬁc plasmids reduced ALT in a dose dependent man-
ner as compared to control, and also reduced IL-1β and improved
liver histology and hepatocyte apoptosis [103]. A role for the IL-1β
pathway is also suggested by the rise in serum IL-1β, peaking at 8 h
after reperfusion. In a different study there was a lack of a difference
in liver injury between wild-type and IL-1R deﬁcient mice which sug-
gests that a role for IL-1β in causing liver injury is either minimal, re-
dundant or limited to certain time points after reperfusion [104].
9. Dermal ﬁbrosis
Systemic sclerosis is a form of scleroderma with deposition of colla-
gen inmany organs including the skin. This results in a scarred and hard
skin surface with redness and pruiritis. The condition is associated with
myoﬁbroblast activation and increased deposition of collagen. A study
examining the up-regulation of gene transcripts in three systemic scle-
rosis cell lines with normal dermal ﬁbroblasts identiﬁed genes among
the inﬂammasomecomponents as being up-regulated [64]. A functional
readout of inﬂammasome activity was increased secretion of IL-1β and
IL-18 by the systemic sclerosis ﬁbroblasts. A causal association between
caspase-1 and ﬁbrogenesis was made by using a caspase-1 inhibitor in
vitrowhich resulted in a decrease in theproduction of collagen 3A1 pro-
tein, and a decrease in α-smooth muscle actin. This was a speciﬁc phe-
nomenon as f-actin remained unchanged. In vivo experiments using a
model of bleomycin-induced dermal ﬁbrosis showed that in NLRP3
and ASC deﬁcient mice there was almost no increase in skin thickness
due to collagen deposition, in contrast to an almost doubling of skin
thickness in wild-type controls. This was correlated by a reduction in
hydroxproline secretion by dermal ﬁbroblasts form these mice. Inter-
estingly this study provided data on the lungs as well, and there was ﬁ-
brosis in the wild-type but not in the knockout mice. This study leaves
open questions about the nature of the initiating DAMP, the origins of
the sensing cell and the relative roles of IL-1β and IL-18.
10. Direct and indirect ﬁbrotic responses of
inﬂammasome activation
An important question is whether the pro-ﬁbrogenic effects of
inﬂammasome activation are due to direct activation of matrix produc-
ing cells such as myoﬁbroblasts by DAMPs, or if the effects are due to
DAMP-induced activation of immune cells such as macrophages with
IL-1β and IL-18-mediated activation of myoﬁbroblasts (Fig. 3). There
is a good experimental evidence to support both pathways. In support
of the direct pathway hepatic stellate cells (HSC) and dermal
ﬁbroblasts both express inﬂammasome components [64,66]. Stimuli
such as uric acid crystals, which are known to activate the NLRP3
inﬂammasome pathway, induce an activation phenotype in HSC cell
lines and primary mouse HSC. Uric acid crystal changes include
up-regulation of TGF-β, collagen1, the development of a more stellate
shape, and the loss of chemotaxis [66]. These changes did not occur if
the HSC were lacking the inﬂammasome component ASC. As stated
above dermal ﬁbroblasts can produce IL-1β, and this can be inhibited
by a caspase-1 inhibitor. Due to the fact that the IL-1R signals via a
MyD88 domain, in common with most Toll receptors, and results in
the up-regulation of pro-IL-1β, the release of IL-1β can initiate a positive
feedback cycle with IL-1β contributing to its own production.
Fig. 3. Direct and indirect pathways of HSC activation: Hepatocyte injury and death induced by various hepatotoxic insults like ethanol, APAP, IR, drugs, toxins and viruses result in
the release of DAMPs/PAMPs along with the enhanced translocation of microbial products across the gut epithelium. These DAMPs/PAMPs may induce activation of hepatic stellate
cells in two ways. (1) Direct activation: HSCs are activated directly through the interaction of DAMPs/PAMPs with the TLRs located on the HSCs as well as by various growth factors
like TGF-β and PDGF released from damaged hepatocytes. (2) Indirect activation: during this pathway, activation of Kupffer cells by DAMPs/PAMPs results in the production and
release of various cytokines like IL-1β and TNF-α. These cytokines then bind with the receptors located on the HSCs and result in their activation that lead to hepatic ﬁbrosis.
Abbreviations: APAP, N-acetyl-p-aminophenol (acetaminophen); IR, ischemia–reperfusion; DAMPs, disease associated molecular patterns; PAMPs, pathogen associated molecular
patterns; HSC, hepatic stellate cell; TLRs, Toll-like receptors; IL-1β,, interleukin-1β; TNF-α, tumor necrosis factor-alpha; LPS, lipopolysaccharide.
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toneal and tissue macrophages such as Kupffer cells are the best char-
acterized cells that respond to inﬂammasome activating signals with
the production of IL-1β and IL-18. The question has been if these cy-
tokines have a role in ﬁbrogenesis. Based on the properties of TGF-β,
which is very ﬁbrogenic but also immunosuppressive it seemed un-
likely that very pro-inﬂammatory cytokines such as IL-1β can also
have pro-ﬁbrogenic properties. During experimental liver ﬁbrosis
IL-1 levels are elevated, and there is signiﬁcantly less liver ﬁbrosis
in IL-1R deﬁcient mice [105]. In an alveolar basal epithelial cell line
IL-1β was shown to stimulate transcription of TGF-β via an NF-κB
and AP-1 pathway [106]. Similar results were obtained from primary
mouse hepatic stellate cells with the up-regulation of collagenα1 and
the down regulation of Bambi [74]. In vivo direct installation of TGF-β
into the lungs resulted in an inﬂammation and ﬁbrogenesis [82]. In
addition cells which are not typically thought of as ﬁbrogenic can un-
dergo a ﬁbrogenic transformation in response to IL-β, and this was
shown to occur for dermal microvascular endothelial cells, whichunderwent a transformation to myoﬁbroblasts with functional colla-
gen synthesis [107].
11. Future developments
These current inﬂammasome activation pathways should be seen
as the minimum activation requirements with the identiﬁcation of
regulatory pathways as high priority. Such regulatory pathways may
account for the differences in scale and type of response in different
mouse strains and individuals, and are candidates for therapeutic in-
tervention. Among the regulatory points of interest are the recently
identiﬁed G protein coupled receptors (GPCRs) which have metabo-
lites such as lactate and beta-hydroxybutyrate as ligands [108]. The
initiation of immune responses in many cells results in a major met-
abolic shift with a decrease in the tricarboxylic cycle and an increase
in glycolysis resulting in the production of molecules such as lactate
and ketone bodies which are ligands for GPCRs and may regulate
inﬂammasome biology [109]. Further areas are the identiﬁcation of
986 X. Ouyang et al. / Biochimica et Biophysica Acta 1832 (2013) 979–988speciﬁc DAMPs which are important in different types of liver injury
and the testing of DAMP and inﬂammasome speciﬁc therapeutic
agents. A diverse range of drugs and molecules including glyburide,
colchicines and anakinra are already under investigation as inhibiting
aspects of inﬂammasome activation [89,110,111]. Some current drugs
such as methotrexate are known to induce chronic liver injury. Eleva-
tion of tissue adenosine levels is thought to be an important mecha-
nism of the action of methotrexate and it will be interesting to test
if adenosine interacts with the inﬂammasome pathway.
In summary a requirement for inﬂammasome components has
been demonstrated in a wide range of ﬁbrotic responses ranging
from the liver, lung and skin. The production of IL-1β and activation
of the IL-1R appears to be a key consequence of inﬂammasome activa-
tion relevant to ﬁbrosis. Most of the data for a role for inﬂammasome
components and IL-1β has come from loss of function experiments
typically involving gene knockout mice. The issue of physiological
inﬂammasome regulation has now taken center stage, and the role
of a wide range of molecules in inﬂammasome regulation is being ac-
tively investigated. Another value of these studies is that they have
identiﬁed many points of therapeutic intervention. This is particularly
exciting for sites such as the IL-1R for which a drug is already in clin-
ical use for the treatment of rheumatoid arthritis.
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